Cargando…

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

BACKGROUND: FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem + nabPTX) were recently introduced for metastatic pancreatic cancer treatment. However, studies that compared these two regimens and studies in Asian populations are lacking. AIM: To compare the treatment outcomes of FOLFIRINOX and Gem...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, In Rae, Kang, Huapyong, Jo, Jung Hyun, Lee, Hee Seung, Chung, Moon Jae, Park, Jeong Youp, Park, Seung Woo, Song, Si Young, An, Chansik, Park, Mi-Suk, Bang, Seungmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031147/
https://www.ncbi.nlm.nih.gov/pubmed/32104549
http://dx.doi.org/10.4251/wjgo.v12.i2.182
_version_ 1783499312714481664
author Cho, In Rae
Kang, Huapyong
Jo, Jung Hyun
Lee, Hee Seung
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
An, Chansik
Park, Mi-Suk
Bang, Seungmin
author_facet Cho, In Rae
Kang, Huapyong
Jo, Jung Hyun
Lee, Hee Seung
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
An, Chansik
Park, Mi-Suk
Bang, Seungmin
author_sort Cho, In Rae
collection PubMed
description BACKGROUND: FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem + nabPTX) were recently introduced for metastatic pancreatic cancer treatment. However, studies that compared these two regimens and studies in Asian populations are lacking. AIM: To compare the treatment outcomes of FOLFIRINOX and Gem + nabPTX regimen for metastatic pancreatic cancer treatment in Korean population. METHODS: Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX (n = 86) or Gem + nabPTX (n = 81) as the first-line since January 2015 were identified using the Severance Hospital Pancreatic Cancer Cohort Registry. Treatment efficacy, treatment-related adverse events and economic aspects were compared. RESULTS: Patients in the FOLFIRINOX group were significantly younger (54 vs 65 years; P < 0.001) and had better performance statuses at diagnosis. The median overall survival (10.7 vs 12.1 mo; P = 0.157), progression-free survival (8.0 vs 8.4 mo; P = 0.134), and objective response rates (33.7% vs 46.9%; P = 0.067) were not significantly different when compared with Gem + nabPTX group. Grade ≥ 3 neutropenia and gastrointestinal adverse events were more common in the FOLFIRINOX group. The drug costs of both regimens were similar. CONCLUSION: Treatment efficacy and economic burdens were comparable between the two regimens. But, the details of adverse event were different. Gem + nabPTX regimen might be considered preferentially in certain conditions.
format Online
Article
Text
id pubmed-7031147
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-70311472020-02-26 FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study Cho, In Rae Kang, Huapyong Jo, Jung Hyun Lee, Hee Seung Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young An, Chansik Park, Mi-Suk Bang, Seungmin World J Gastrointest Oncol Retrospective Cohort Study BACKGROUND: FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem + nabPTX) were recently introduced for metastatic pancreatic cancer treatment. However, studies that compared these two regimens and studies in Asian populations are lacking. AIM: To compare the treatment outcomes of FOLFIRINOX and Gem + nabPTX regimen for metastatic pancreatic cancer treatment in Korean population. METHODS: Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX (n = 86) or Gem + nabPTX (n = 81) as the first-line since January 2015 were identified using the Severance Hospital Pancreatic Cancer Cohort Registry. Treatment efficacy, treatment-related adverse events and economic aspects were compared. RESULTS: Patients in the FOLFIRINOX group were significantly younger (54 vs 65 years; P < 0.001) and had better performance statuses at diagnosis. The median overall survival (10.7 vs 12.1 mo; P = 0.157), progression-free survival (8.0 vs 8.4 mo; P = 0.134), and objective response rates (33.7% vs 46.9%; P = 0.067) were not significantly different when compared with Gem + nabPTX group. Grade ≥ 3 neutropenia and gastrointestinal adverse events were more common in the FOLFIRINOX group. The drug costs of both regimens were similar. CONCLUSION: Treatment efficacy and economic burdens were comparable between the two regimens. But, the details of adverse event were different. Gem + nabPTX regimen might be considered preferentially in certain conditions. Baishideng Publishing Group Inc 2020-02-15 2020-02-15 /pmc/articles/PMC7031147/ /pubmed/32104549 http://dx.doi.org/10.4251/wjgo.v12.i2.182 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Cho, In Rae
Kang, Huapyong
Jo, Jung Hyun
Lee, Hee Seung
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
An, Chansik
Park, Mi-Suk
Bang, Seungmin
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
title FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
title_full FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
title_fullStr FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
title_full_unstemmed FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
title_short FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
title_sort folfirinox vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031147/
https://www.ncbi.nlm.nih.gov/pubmed/32104549
http://dx.doi.org/10.4251/wjgo.v12.i2.182
work_keys_str_mv AT choinrae folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT kanghuapyong folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT jojunghyun folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT leeheeseung folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT chungmoonjae folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT parkjeongyoup folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT parkseungwoo folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT songsiyoung folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT anchansik folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT parkmisuk folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy
AT bangseungmin folfirinoxvsgemcitabinenabpaclitaxelfortreatmentofmetastaticpancreaticcancersinglecentercohortstudy